






FIG. 1

SUBSTITUTE SHEET (RULE 26)




Subunit	Model Predicted Value (1%)	Average Sequence Coverage (%)	% RSD	% Difference
Fc/2	61.9	61.0	1.6	-1.4
LC	65.3	62.0	4.3	-5.1
Fd	48.2	48.0	1.7	-0.5

FIG. 2A



Run	Model Predicted Value	Average Number of Fragments	% RSD	% Difference
Low	111	106	7.2	-4.1
Medium	138	124	7.9	-10.3
High	39	40	2.5	2.3

FIG. 2B



		Fragment Size (Da)		
		"Low"	"Medium"	"High"
Fc/2	Lower Quartile	2866	3494	3855
	Median	4435	5431	6023
	Upper Quartile	6718	7599	10252
LC	Lower Quartile	3640	4500	4484
	Median	5729	6931	6931
	Upper Quartile	7909	9172	9354
Fd	Lower Quartile	2704	2803	3596
	Median	5229	5646	6681
	Upper Quartile	7610	8267	9693

FIG. 2C

5/9

Fc/2

N G P S V F L F P P K P K D T L M I S R T P E V T T C 25
 26 M V I D V S H E D P E V K F N W Y M D G M E V H N 50
 51 A K T K P R E E Q Y N S T Y R V V S V L T V L H Q 75
 76 D W L N G K E Y K C K V S L N K A L P A P I L E K L T I 100
 101 S L K A K G Q P R E P L Q V Y T L P L S R L E L M T L K N 125
 126 Q L V S L T C L V K G L F Y P S I D I A V L E W E S L N G L Q 150
 151 P E I N N Y K T T I P P V L L D S I D G S F L L L Y S K L L T 175
 176 M D K L S R W Q Q G N V F S C L S V M H E A L L H N H L Y 200
 201 I T Q K L S L S L S P T G C

71%

LC

N D I Q M T Q S P S T L S A S V G D R V T I T C S A 25
 26 S S R V G Y M H W Y Q Q K P G K A P K L L I Y D T 50
 51 S K L A S G V P S R F S G S G S G T E F T L T I L S 75
 76 S L Q P D D F A T Y Y C F Q G S G Y P F T F G G G 100
 101 T K V E L I K R T V A L A P S V F I F I P P S I D E L Q L K 125
 126 S L G T A S V M C L L N N F Y P R E I A K V Q W K L V D 150
 151 L A L L Q S G N S Q E L S V T L E Q D S K L S L T Y S L L S 175
 176 S L T L T L S K A D Y E K H K V L Y A C E V L T H Q G L 200
 201 S L S P L V T K L S F N R G E C C

□ PTM

 c_z
 b_y

74%

Fd


N Q V T L R E S G P A L V K P T Q T L T L T Q T F S 25
 26 G F S L S T A G M S V G W I R Q P P G K A L E W L 50
 51 A D I W W D D K K H Y N P S L K D R L T I S K D T 75
 76 S K N Q V V L K V T N M D P A D T A T Y Y C A R D 100
 101 M I F N F Y F D V W G Q G T T V T V S S A S T K G 125
 126 P S V F P L A P S S K S T L S G G T A A L G C L V K 150
 151 D Y F P L E P V T V S W N S L G L L T S G V H T F P L A 175
 176 V L L Q S S G L L Y S L L S L V V T V P S L S L L G T Q T 200
 201 Y I Q N V N H K P S N T K V L D K R M E P K S C D K 225
 226 T H T C P P Q P A P E L L G C

58%

FIG. 3A

SUBSTITUTE SHEET (RULE 26)

6/9

2 Low LCMS² Runs

Fc/2 N G P S V F L F P P K P K D T L M I S R T P E V T C 25
 26 V V V D V S H E D P E V K F N W Y V D G V E V H N 50
 51 A K T K P R E E Q Y N S T Y R V V S V L T V L H Q 75
 76 D W L N G K E Y K C K V S N K A L P A P I E K T U 100
 101 S K A K G L Q P R L E P L Q V Y T L P L S R L E E M T K N 125
 126 L Q V L S L T C L V L K G F L Y P L S D L I A V L E W L E S N G L Q 150
 151 L P E L N N L Y K L T T P P L V L L D L S D L G L S F L L Y L S K L L T 175
 176 L V D L K L S R W L Q L G L N V L F L S C L S L V M H E A L L H L N H L Y 200
 201 L T L Q L K L S L L S L L S P G C

66% Coverage

LC N D I Q M T Q S P S T L S A S V G D R V T I T C S A 25
 26 S S R V G Y M H W Y Q Q K P G K A P K L L I Y D T 50
 51 S K L A S G V P S R F S G S G S G T E F T L I S 75
 76 S L L Q P D D F A T Y Y C F Q G S G Y P F T F G L G G 100
 101 T K L V E L K R L T V A A P S V L F I F P P L S D L E L Q L K 125
 126 S G T A S V V L C L L N N L F Y P R L E A K L V L Q W K L V D 150
 151 N A L L Q L S G N S L Q E S L V L E L Q D L S K D S T L Y S L L S 175
 176 S T L L T L L S K L A D Y L E K L H K L V L Y A L C E L V L H L Q G L 200
 201 S L S L P L V L T K L S F L N R G E T C C

72% Coverage

Fd N Q V T L R E S G P A L V K P T Q T L T L T C T F S 25
 26 G F S L S T A G M S V G W I R Q P P G K A L E W L 50
 51 A D N W W D D K K H Y N P S L K D R L T I S K D T 75
 76 S K N Q V V L K V I T N M D P A D T A T Y Y C A R D 100
 101 L M I F N F Y F D V W G Q G T T V T V L S A S L T K L G 125
 126 P S V F P L A P S S K S T S G G T A A L G C L V K 150
 151 D Y F P E L P V L T V L S W L N S G L A L L T S L G V H T F P L A 175
 176 L V L L Q L S L G L L Y L S L L S L V L V L T V L P S L S L L G T Q L T 200
 201 L Y I C L N V L N H L K P L S N L T K L V L D K L R L V L E P L K L S C L D L K 225
 226 L T H T C L P P L C P A L P E L L T G C

54% Coverage

FIG. 3B
SUBSTITUTE SHEET (RULE 26)

2 Low + 2 Mid LCMS² Runs

N G PLS VIFLIFP PJK P[KIDITLIM IISRTT PEIFVITC 25
 26 VIVVD VISHEIDIPETVKFNWYVIDGVIEVHN 50
 51 AKIK PIREEQYNS T YLR V VISVL T V L H Q 75
 76 D W LLNGLK E YLK C K V S NKA L PLA P IELKTLI 100
 101 SLK ALKGLQ P RLE PLQ V Y TLL PLPLSLRLEELMTLKIN 125
 126 LQLVLS L T CLLVLK GLFY PLSDLIALVLELWELSINGLQ 150
 151 LP ELNINLYKLT T PLPLVLLDLSDLGLSLFLFLLYSLKLLT 175
 176 LVLDKLSLRWLQLQLGN VFLS CLSLVLM H E ALLHNLHLY 200
 201 LTQLKLSLLSLL S P G C

75% Coverage

N D I QIMTQIS P S TILSIAVS VIG DTR V T I T CISA 25
 26 S SRTVGYMHWYQLQK P GKLA P K L L L I Y D T 50
 51 SIKL ASIGVVPISRFISGISGSGTTEFTITLITIS 75
 76 SLLQIPDIDFA T Y Y C FQIGSISGYLPF TFGG G 100
 101 TIKVETIK RLT VIA A PLS VFIIFPPLSDLEQ LK 125
 126 SIGT ALS VVLC L LNTNIFY PIREIAKLVQWKLV D 150
 151 NIAL LQS GNLSQFESVTELEQDLS KD SITLYSLS 175
 176 SITLL TLLSKIALDYELKHKLVLVYLAIC ELVTLHQ G 200
 201 SLSLPVLT KLSFLNR G ETC

82% Coverage

N QLV T LRISIGPIALIVK PITQITLITITITCIT FIS 25
 26 GIFS L SITAG M SIVG W I RIQ P PIGKIALITEWL 50
 51 ADITWWDID KIK H YIN PISLIDIRITITISKIDIT 75
 76 SIKINQIV VILKIVIT NMD P A D T AT Y Y C A R D 100
 101 LM I F NF YIFD VWIGQ G T T V T VLSLS ALSIT KLG 125
 126 P S VIFP LIA P S S K S TLS G GIT A A L G C L V K 150
 151 DLYF P ELP VLTVLS WLN SLGLA LITSLG VEH TIF PLA 175
 176 LVLLQSLSGLLYS LLSLVVLT VLP SLSLLG T QIT 200
 201 LY I CUN VLNHLK PLSNLT KLVLDKLRVLELPKLS CLDK 225
 226 LTH T CLP PLC P ALP E L LIG C

64% Coverage

FIG. 3B (Cont.)
SUBSTITUTE SHEET (RULE 26)

2 Low + 2 Mid + 2High LCMS² Runs

N G PLS VIFLIFP PJK P[KIDITLIM IISRTT PEIFVITC 25
 26 VIVVD VISHEIDIPETV KFNWYVIDG VEIFVIN 50
 51 AKIK PIRELEQYINLSIT YLR V VISVIL T V L H Q 75
 76 D W LLNGLK E YLK C K V SLNKA LPLALPLLEKLT 100
 101 LSK ALKGLQ P RLE PLQ V Y TLL PLPLSLRLEELMTKIN 125
 126 LQVLS L T CLLVLK GFLY PLSDLIALVLELWLESLNGLQ 150
 151 LP ELNINLYKLT T PLPLVLLDLSDLGLSLFLLLYSLKLLT 175
 176 LVLDKLSLRWLQLQLGN VFELS CLSLVLM H E ALLHNLHLY 200
 201 LTQLKLSLLSLL S P G C

78% Coverage

N D I QIMTQIS P S TILSIAVS VIG DIR V T I T CISA 25
 26 S SRTVIGYIMHWYQLQK P GKLA P[KL LLYIDIT 50
 51 SIKL ASIGVPI SRTFISGISGISGTTEFTITITIS 75
 76 SLLQIPIDIDFAIT YLYCFIQGISYGPFTITFVGIG 100
 101 TIKVLEIK RLT VIA A PLS VFITIFPPLSDIEQ LK 125
 126 LSGIT ALS VVLC L LNTNIFY PIREIAKLVQWKVLD 150
 151 NIAL LQS GNLSQLFSLVTEQDLS KD SITLYSLLS 175
 176 SITLL TLLSKIALDYELKHKLVLVYLAIC ELVTHIQ GL 200
 201 SLSLPVITKLSFLNR G ETC

84% Coverage

N QLV T LRISGIPALIVK PITQITLITITITITIT FIS 25
 26 GIFS LSTIAIG M SIVIG W I RIQ P PIGKIALTEWL 50
 51 ADIDWWDID KIKH YIN PISLLKIDIRITITISKIDIT 75
 76 SIKINQIV VILKIVLTIN MD P AD T ATTYIY C A R D 100
 101 M IIF NIF YIFD VWGLQ G T T V TVLSLS ALSIT KLG 125
 126 P S VFIP LLA P SISK S TISG GIT A A L G C L V K 150
 151 DLYFPLELP VLTIVLS WLN SLGLALLTSLG VHLTIF PLA 175
 176 LVLLQSLSLGLLYSLLSLSLVLTIVLP SLSLSLLG T QIT 200
 201 LY I CUNLVNLHK PLSNLTKLVDKLRVLELPKLS CLDK 225
 226 LT H T CLP PLC P ALP E LITGC

71% Coverage

FIG. 3B (Cont.)
 SUBSTITUTE SHEET (RULE 26)

Dupilumab Heavy Chain SEQ ID NO: 1

EVQLVESGGG LEQPGGSLRL SCAGSGFTR DYAMTWVRQA PGKGLEWVSS ISSSGGNTYY ADSVKGRFTI SRDNSKNTLY
LQMSLRAED TAVYYCAKDR LSITIRPRYY GLDWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTKITYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPEFL
GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV LTVLHQDWLNL
GKEYCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTTP
PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC SVMHEALHNIH YTKQSLSLSL GK¹⁵²

Dupilumab Light Chain SEQ ID NO: 2

DIVMTQSPLS LPVTPGEPAS ISCRSSQSLL YSIGYNYLDW YLQKSGQSPQ LLIYLGSNRA SGVPDRFSGS GSGTDFTLKT
SRVEAEDVGF YYCMQALQTP YTFGGGTKLE IKRTVAAFSV FIFPPSDEQL KSGTASVWC LNNFYBREAK VQWKVDHALQ
SGNSQESVTE QDSKDYSTSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC²¹⁹

FIG. 4